Christiane Pott
Expertise in
9
conditions

Christiane Pott

Arnold Heller Str. 3, 
Kiel, SH, DE 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
9
conditions
Arnold Heller Str. 3, 
Kiel, SH, DE 
OverviewLocationsClinical Research

Overview

Christiane Pott practices in Kiel, Germany. Ms. Pott is highly rated in 9 conditions, according to our data. Her top areas of expertise are Mantle Cell Lymphoma (MCL), Non-Hodgkin Lymphoma, Follicular Lymphoma, B-Cell Lymphoma, and Bone Marrow Transplant.

Her clinical research consists of co-authoring 110 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender
Female

Locations

Arnold Heller Str. 3, Kiel, SH 24105, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

Autologous Transplantation After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma - a Randomized European Mcl Network Trial
Autologous Transplantation After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma - a Randomized European Mcl Network Trial
Enrollment Status: Recruiting
Publish Date: December 19, 2017
Intervention Type: Drug
Study Drugs: R-CHOP/R-DHAP, Ibrutinib (Induction), ASCT Conditioning, Ibrutinib (Maintenance)
Study Phase: Phase 3
Obinutuzumab in Marginal Zone Lymphoma (OLYMP-1)
Obinutuzumab in Marginal Zone Lymphoma (OLYMP-1)
Enrollment Status: Active_not_recruiting
Publish Date: April 04, 2025
Intervention Type: Drug
Study Drug: Obinutuzumab
Study Phase: Phase 2
Efficacy of Alternating Immunochemotherapy Consisting of R-CHOP + R-HAD vs R-CHOP Alone, Followed by Maintenance Therapy Consisting of Additional Lenalidomide + Rituximab vs Rituximab Alone for Older Patients With Mantle Cell Lymphoma
Efficacy of Alternating Immunochemotherapy Consisting of R-CHOP + R-HAD vs R-CHOP Alone, Followed by Maintenance Therapy Consisting of Additional Lenalidomide + Rituximab vs Rituximab Alone for Older Patients With Mantle Cell Lymphoma
Enrollment Status: Completed
Publish Date: March 05, 2025
Intervention Type: Drug
Study Drugs: R-CHOP, R-CHOP/R-HAD, Rituximab, Lenalidomide
Study Phase: Phase 3
Expanded Access Program for Pirtobrutinib for Previously Treated B-Cell Cancers
Expanded Access Program for Pirtobrutinib for Previously Treated B-Cell Cancers
Enrollment Status: Approved_for_marketing
Publish Date: December 18, 2024
Intervention Type: Drug
View 3 Less Clinical Trials

110 Total Publications

The MCL elderly III trial protocol: an international, randomized, open-label phase II trial to investigate the combinations of venetoclax, ibrutinib and rituximab or bendamustine, ibrutinib and rituximab in patients with treatment naive mantle cell lymphoma not eligible for dose-intensive treatment.
The MCL elderly III trial protocol: an international, randomized, open-label phase II trial to investigate the combinations of venetoclax, ibrutinib and rituximab or bendamustine, ibrutinib and rituximab in patients with treatment naive mantle cell lymphoma not eligible for dose-intensive treatment.
Journal: BMC cancer
Published: May 27, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Pott's expertise for a condition
ConditionClose
View All 7 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile